Nesfatin‐1 inhibits cerebral aneurysms by activating Nrf2 and inhibiting NF‐κB signaling
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14864 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Huimin Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China. Hauptthemen laut MEDLINE: Intracranial Aneurysm, NF-E2-Related Factor 2, NF-kappa B, Nucleobindins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Talent Development Foundation of The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan Science and Technology of Social Development Program.
Abstract (Originalsprache)
Aims
Cerebral aneurysm (CA) has been considered one of the most common cerebrovascular diseases, affecting millions of people worldwide. A therapeutic agent is currently missing for the treatment of CA. Nesfatin‐1 (Nes‐1) is an 82‐amino acid adipokine which possesses a wide range of biological functions. However, the physiological function of Nes‐1 in CA is still unknown. Here, we aimed to assess the preventive effects of Nes‐1 in the pathological development of CA and elucidate the mechanisms behind this.
Methods
We used an elastase‐induced CA model, accompanied by a high‐salt diet to induce hypertension. Additionally, diverse experimental techniques, including Verhoeff‐Van Gieson staining, real time PCR, enzyme‐linked immuno sorbent assay (ELISA), and immunofluorescence staining, were employed to assess CA formation, gene and protein expression, as well as the macrophage infiltration.
Results
Our results indicate that administration of Nes‐1 significantly decreased the aneurysm size. Additionally, Nes‐1 prevented inflammatory response by inhibiting the expression of interleukin‐6 (IL‐6), tumor necrosis factor‐α (TNF‐α), and monocyte chemoattractant protein 1 (MCP‐1) at both the mRNA and protein levels in the Circle of Willis (COW) region. Also, the increased levels of matrix metalloproteinase‐2 (MMP‐2) and matrix metalloproteinase‐9 (MMP‐9) in the COW region were reduced by Nes‐1. We found that Nes‐1 administration suppressed the invasion of macrophages. Mechanistically, Nes‐1 activated Nrf‐2 by promoting its nuclear translocation but prevented the activation of the IκBα/NF‐κB signaling pathway.
Conclusion
These findings suggest that Nes‐1 might be used as a promising agent for the prevention of CA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
- Department of Neurosurgery, Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases, Capital Medical University, Beijing, China.
- Department of Neurosurgery, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
- Department of Neurosurgery, Minzu Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Förderung
- Talent Development Foundation of The First Dongguan Affiliated Hospital of Guangdong Medical University
- Dongguan Science and Technology of Social Development Program
Zitieren
APA
Yu, H., Liu, Q., Xie, M., Fan, J., Luo, J., Huang, J., & Chen, L. (2024). Nesfatin‐1 inhibits cerebral aneurysms by activating Nrf2 and inhibiting NF‐κB signaling. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14864
Vancouver
Yu H, Liu Q, Xie M, Fan J, Luo J, Huang J, et al. Nesfatin‐1 inhibits cerebral aneurysms by activating Nrf2 and inhibiting NF‐κB signaling. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14864
BibTeX
@article{Yu2024,
author = {Yu, Huimin and Liu, Qingyuan and Xie, Minghong and Fan, Junquan and Luo, Jiajia and Huang, Junping and Chen, Lei},
title = {Nesfatin‐1 inhibits cerebral aneurysms by activating Nrf2 and inhibiting NF‐κB signaling},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14864}
}
EUVIMED